nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfamethoxazole—UGT1A9—Sorafenib—thyroid cancer	0.318	0.447	CbGbCtD
Sulfamethoxazole—ALB—Vandetanib—thyroid cancer	0.164	0.23	CbGbCtD
Sulfamethoxazole—CYP2C8—Sorafenib—thyroid cancer	0.0763	0.107	CbGbCtD
Sulfamethoxazole—CYP2C9—Sorafenib—thyroid cancer	0.0532	0.0747	CbGbCtD
Sulfamethoxazole—CYP3A4—Vandetanib—thyroid cancer	0.0513	0.072	CbGbCtD
Sulfamethoxazole—CYP3A4—Sorafenib—thyroid cancer	0.0309	0.0434	CbGbCtD
Sulfamethoxazole—CYP3A4—Doxorubicin—thyroid cancer	0.0188	0.0263	CbGbCtD
Sulfamethoxazole—PTGS1—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00472	0.104	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00355	0.0785	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metapathway biotransformation—CHST14—thyroid cancer	0.00206	0.0455	CbGpPWpGaD
Sulfamethoxazole—Infestation—Vandetanib—thyroid cancer	0.00205	0.00846	CcSEcCtD
Sulfamethoxazole—Depression—Vandetanib—thyroid cancer	0.00204	0.00844	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00203	0.00839	CcSEcCtD
Sulfamethoxazole—Renal failure—Vandetanib—thyroid cancer	0.00201	0.00832	CcSEcCtD
Sulfamethoxazole—Stomatitis—Vandetanib—thyroid cancer	0.002	0.00825	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00194	0.008	CcSEcCtD
Sulfamethoxazole—PTGS1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00193	0.0427	CbGpPWpGaD
Sulfamethoxazole—Dermatitis exfoliative—Sorafenib—thyroid cancer	0.0019	0.00785	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Vandetanib—thyroid cancer	0.00182	0.0075	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Vandetanib—thyroid cancer	0.0018	0.00745	CcSEcCtD
Sulfamethoxazole—Hyponatraemia—Sorafenib—thyroid cancer	0.0018	0.00744	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Vandetanib—thyroid cancer	0.00174	0.00718	CcSEcCtD
Sulfamethoxazole—Eye disorder—Vandetanib—thyroid cancer	0.00172	0.0071	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Vandetanib—thyroid cancer	0.00166	0.00685	CcSEcCtD
Sulfamethoxazole—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00162	0.00667	CcSEcCtD
Sulfamethoxazole—Mental disorder—Vandetanib—thyroid cancer	0.00161	0.00665	CcSEcCtD
Sulfamethoxazole—Malnutrition—Vandetanib—thyroid cancer	0.0016	0.00661	CcSEcCtD
Sulfamethoxazole—Pancreatitis—Sorafenib—thyroid cancer	0.00152	0.00628	CcSEcCtD
Sulfamethoxazole—Eruption—Epirubicin—thyroid cancer	0.00148	0.00613	CcSEcCtD
Sulfamethoxazole—NAT1—Biological oxidations—RXRA—thyroid cancer	0.00146	0.0324	CbGpPWpGaD
Sulfamethoxazole—Neutropenia—Sorafenib—thyroid cancer	0.00145	0.00599	CcSEcCtD
Sulfamethoxazole—Cough—Vandetanib—thyroid cancer	0.0014	0.00577	CcSEcCtD
Sulfamethoxazole—Pneumonia—Sorafenib—thyroid cancer	0.00139	0.00574	CcSEcCtD
Sulfamethoxazole—Convulsion—Vandetanib—thyroid cancer	0.00139	0.00573	CcSEcCtD
Sulfamethoxazole—Infestation—Sorafenib—thyroid cancer	0.00138	0.00571	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Sorafenib—thyroid cancer	0.00138	0.00571	CcSEcCtD
Sulfamethoxazole—Eruption—Doxorubicin—thyroid cancer	0.00137	0.00567	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00137	0.00566	CcSEcCtD
Sulfamethoxazole—Arthralgia—Vandetanib—thyroid cancer	0.00136	0.00563	CcSEcCtD
Sulfamethoxazole—Renal failure—Sorafenib—thyroid cancer	0.00136	0.00561	CcSEcCtD
Sulfamethoxazole—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00136	0.00559	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00135	0.00559	CcSEcCtD
Sulfamethoxazole—Bone marrow depression—Epirubicin—thyroid cancer	0.00135	0.00559	CcSEcCtD
Sulfamethoxazole—Stomatitis—Sorafenib—thyroid cancer	0.00135	0.00556	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00131	0.0054	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Vandetanib—thyroid cancer	0.00128	0.00529	CcSEcCtD
Sulfamethoxazole—PTGS1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00128	0.0284	CbGpPWpGaD
Sulfamethoxazole—Thrombocytopenia—Vandetanib—thyroid cancer	0.00128	0.00528	CcSEcCtD
Sulfamethoxazole—Skin disorder—Vandetanib—thyroid cancer	0.00127	0.00524	CcSEcCtD
Sulfamethoxazole—Bone marrow depression—Doxorubicin—thyroid cancer	0.00125	0.00517	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Sorafenib—thyroid cancer	0.00123	0.00506	CcSEcCtD
Sulfamethoxazole—Neuritis—Epirubicin—thyroid cancer	0.00122	0.00505	CcSEcCtD
Sulfamethoxazole—Connective tissue disorder—Sorafenib—thyroid cancer	0.00122	0.00504	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Sorafenib—thyroid cancer	0.00122	0.00502	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00119	0.00492	CcSEcCtD
Sulfamethoxazole—Insomnia—Vandetanib—thyroid cancer	0.00118	0.00488	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Sorafenib—thyroid cancer	0.00117	0.00484	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Vandetanib—thyroid cancer	0.00117	0.00481	CcSEcCtD
Sulfamethoxazole—Tinnitus—Sorafenib—thyroid cancer	0.00116	0.00478	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Vandetanib—thyroid cancer	0.00115	0.00475	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Vandetanib—thyroid cancer	0.00114	0.00469	CcSEcCtD
Sulfamethoxazole—Neuritis—Doxorubicin—thyroid cancer	0.00113	0.00467	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00113	0.00466	CcSEcCtD
Sulfamethoxazole—Fatigue—Vandetanib—thyroid cancer	0.00113	0.00465	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Sorafenib—thyroid cancer	0.00112	0.00463	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Sorafenib—thyroid cancer	0.00112	0.00462	CcSEcCtD
Sulfamethoxazole—Blood disorder—Epirubicin—thyroid cancer	0.00109	0.00451	CcSEcCtD
Sulfamethoxazole—Mental disorder—Sorafenib—thyroid cancer	0.00109	0.00449	CcSEcCtD
Sulfamethoxazole—Malnutrition—Sorafenib—thyroid cancer	0.00108	0.00446	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—MINPP1—thyroid cancer	0.00107	0.0238	CbGpPWpGaD
Sulfamethoxazole—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00107	0.00441	CcSEcCtD
Sulfamethoxazole—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00104	0.00429	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Vandetanib—thyroid cancer	0.00103	0.00427	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Vandetanib—thyroid cancer	0.00103	0.00427	CcSEcCtD
Sulfamethoxazole—UGT1A9—PPAR Alpha Pathway—CDK1—thyroid cancer	0.00103	0.0228	CbGpPWpGaD
Sulfamethoxazole—Blood disorder—Doxorubicin—thyroid cancer	0.00101	0.00418	CcSEcCtD
Sulfamethoxazole—Glossitis—Epirubicin—thyroid cancer	0.000991	0.00409	CcSEcCtD
Sulfamethoxazole—Oliguria—Epirubicin—thyroid cancer	0.000991	0.00409	CcSEcCtD
Sulfamethoxazole—Angioedema—Sorafenib—thyroid cancer	0.000987	0.00408	CcSEcCtD
Sulfamethoxazole—Leukopenia—Sorafenib—thyroid cancer	0.000967	0.00399	CcSEcCtD
Sulfamethoxazole—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.000962	0.00397	CcSEcCtD
Sulfamethoxazole—UGT1A9—PPAR Alpha Pathway—RXRA—thyroid cancer	0.000957	0.0212	CbGpPWpGaD
Sulfamethoxazole—Cough—Sorafenib—thyroid cancer	0.000943	0.00389	CcSEcCtD
Sulfamethoxazole—Asthenia—Vandetanib—thyroid cancer	0.000938	0.00387	CcSEcCtD
Sulfamethoxazole—Pruritus—Vandetanib—thyroid cancer	0.000925	0.00382	CcSEcCtD
Sulfamethoxazole—Myalgia—Sorafenib—thyroid cancer	0.00092	0.0038	CcSEcCtD
Sulfamethoxazole—Arthralgia—Sorafenib—thyroid cancer	0.00092	0.0038	CcSEcCtD
Sulfamethoxazole—Oliguria—Doxorubicin—thyroid cancer	0.000917	0.00379	CcSEcCtD
Sulfamethoxazole—Glossitis—Doxorubicin—thyroid cancer	0.000917	0.00379	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000913	0.00377	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—NDUFA13—thyroid cancer	0.000913	0.0202	CbGpPWpGaD
Sulfamethoxazole—Hyperkalaemia—Epirubicin—thyroid cancer	0.000897	0.0037	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Vandetanib—thyroid cancer	0.000894	0.00369	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Sorafenib—thyroid cancer	0.000882	0.00364	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Sorafenib—thyroid cancer	0.000865	0.00357	CcSEcCtD
Sulfamethoxazole—Dizziness—Vandetanib—thyroid cancer	0.000864	0.00357	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Sorafenib—thyroid cancer	0.000863	0.00356	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—CHST14—thyroid cancer	0.000858	0.019	CbGpPWpGaD
Sulfamethoxazole—Aplastic anaemia—Epirubicin—thyroid cancer	0.000857	0.00354	CcSEcCtD
Sulfamethoxazole—Skin disorder—Sorafenib—thyroid cancer	0.000856	0.00354	CcSEcCtD
Sulfamethoxazole—Anorexia—Sorafenib—thyroid cancer	0.00084	0.00347	CcSEcCtD
Sulfamethoxazole—Vomiting—Vandetanib—thyroid cancer	0.000831	0.00343	CcSEcCtD
Sulfamethoxazole—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00083	0.00343	CcSEcCtD
Sulfamethoxazole—CYP2C8—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000827	0.0183	CbGpPWpGaD
Sulfamethoxazole—Rash—Vandetanib—thyroid cancer	0.000824	0.0034	CcSEcCtD
Sulfamethoxazole—Dermatitis—Vandetanib—thyroid cancer	0.000823	0.0034	CcSEcCtD
Sulfamethoxazole—Headache—Vandetanib—thyroid cancer	0.000819	0.00338	CcSEcCtD
Sulfamethoxazole—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.000812	0.018	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000811	0.018	CbGpPWpGaD
Sulfamethoxazole—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000803	0.00332	CcSEcCtD
Sulfamethoxazole—Aplastic anaemia—Doxorubicin—thyroid cancer	0.000793	0.00328	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Sorafenib—thyroid cancer	0.000786	0.00325	CcSEcCtD
Sulfamethoxazole—Nausea—Vandetanib—thyroid cancer	0.000776	0.00321	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Sorafenib—thyroid cancer	0.000776	0.0032	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Sorafenib—thyroid cancer	0.000766	0.00316	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000761	0.00314	CcSEcCtD
Sulfamethoxazole—Fatigue—Sorafenib—thyroid cancer	0.00076	0.00314	CcSEcCtD
Sulfamethoxazole—Photosensitivity—Epirubicin—thyroid cancer	0.000755	0.00312	CcSEcCtD
Sulfamethoxazole—Vascular purpura—Epirubicin—thyroid cancer	0.000741	0.00306	CcSEcCtD
Sulfamethoxazole—ALB—Recycling of bile acids and salts—RXRA—thyroid cancer	0.000739	0.0164	CbGpPWpGaD
Sulfamethoxazole—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000721	0.00298	CcSEcCtD
Sulfamethoxazole—UGT1A9—Metapathway biotransformation—CHST14—thyroid cancer	0.000715	0.0158	CbGpPWpGaD
Sulfamethoxazole—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000703	0.0029	CcSEcCtD
Sulfamethoxazole—Urticaria—Sorafenib—thyroid cancer	0.0007	0.00289	CcSEcCtD
Sulfamethoxazole—Photosensitivity—Doxorubicin—thyroid cancer	0.000699	0.00288	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Sorafenib—thyroid cancer	0.000697	0.00288	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Sorafenib—thyroid cancer	0.000697	0.00288	CcSEcCtD
Sulfamethoxazole—Renal impairment—Epirubicin—thyroid cancer	0.000697	0.00288	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—HPGD—thyroid cancer	0.000692	0.0153	CbGpPWpGaD
Sulfamethoxazole—Purpura—Epirubicin—thyroid cancer	0.000688	0.00284	CcSEcCtD
Sulfamethoxazole—Vascular purpura—Doxorubicin—thyroid cancer	0.000686	0.00283	CcSEcCtD
Sulfamethoxazole—Hypoglycaemia—Epirubicin—thyroid cancer	0.000679	0.0028	CcSEcCtD
Sulfamethoxazole—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000673	0.0149	CbGpPWpGaD
Sulfamethoxazole—Hyponatraemia—Epirubicin—thyroid cancer	0.000666	0.00275	CcSEcCtD
Sulfamethoxazole—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00065	0.00268	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Sorafenib—thyroid cancer	0.00065	0.00268	CcSEcCtD
Sulfamethoxazole—Renal impairment—Doxorubicin—thyroid cancer	0.000645	0.00266	CcSEcCtD
Sulfamethoxazole—Purpura—Doxorubicin—thyroid cancer	0.000636	0.00263	CcSEcCtD
Sulfamethoxazole—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—thyroid cancer	0.000636	0.0141	CbGpPWpGaD
Sulfamethoxazole—Asthenia—Sorafenib—thyroid cancer	0.000633	0.00261	CcSEcCtD
Sulfamethoxazole—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000629	0.0026	CcSEcCtD
Sulfamethoxazole—Pruritus—Sorafenib—thyroid cancer	0.000624	0.00258	CcSEcCtD
Sulfamethoxazole—Ataxia—Epirubicin—thyroid cancer	0.000623	0.00257	CcSEcCtD
Sulfamethoxazole—Hyponatraemia—Doxorubicin—thyroid cancer	0.000616	0.00254	CcSEcCtD
Sulfamethoxazole—NAT2—Biological oxidations—RXRA—thyroid cancer	0.000607	0.0134	CbGpPWpGaD
Sulfamethoxazole—Diarrhoea—Sorafenib—thyroid cancer	0.000603	0.00249	CcSEcCtD
Sulfamethoxazole—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000597	0.00246	CcSEcCtD
Sulfamethoxazole—Dizziness—Sorafenib—thyroid cancer	0.000583	0.00241	CcSEcCtD
Sulfamethoxazole—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000581	0.0129	CbGpPWpGaD
Sulfamethoxazole—Ataxia—Doxorubicin—thyroid cancer	0.000577	0.00238	CcSEcCtD
Sulfamethoxazole—Eosinophilia—Epirubicin—thyroid cancer	0.000567	0.00234	CcSEcCtD
Sulfamethoxazole—Pancreatitis—Epirubicin—thyroid cancer	0.000562	0.00232	CcSEcCtD
Sulfamethoxazole—Vomiting—Sorafenib—thyroid cancer	0.000561	0.00231	CcSEcCtD
Sulfamethoxazole—Rash—Sorafenib—thyroid cancer	0.000556	0.0023	CcSEcCtD
Sulfamethoxazole—Dermatitis—Sorafenib—thyroid cancer	0.000555	0.00229	CcSEcCtD
Sulfamethoxazole—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000552	0.00228	CcSEcCtD
Sulfamethoxazole—Headache—Sorafenib—thyroid cancer	0.000552	0.00228	CcSEcCtD
Sulfamethoxazole—Pancytopenia—Epirubicin—thyroid cancer	0.000544	0.00225	CcSEcCtD
Sulfamethoxazole—Neutropenia—Epirubicin—thyroid cancer	0.000536	0.00221	CcSEcCtD
Sulfamethoxazole—Eosinophilia—Doxorubicin—thyroid cancer	0.000525	0.00217	CcSEcCtD
Sulfamethoxazole—Nausea—Sorafenib—thyroid cancer	0.000524	0.00216	CcSEcCtD
Sulfamethoxazole—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000523	0.00216	CcSEcCtD
Sulfamethoxazole—Pancreatitis—Doxorubicin—thyroid cancer	0.00052	0.00215	CcSEcCtD
Sulfamethoxazole—Pneumonia—Epirubicin—thyroid cancer	0.000514	0.00212	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Epirubicin—thyroid cancer	0.000511	0.00211	CcSEcCtD
Sulfamethoxazole—Infestation—Epirubicin—thyroid cancer	0.000511	0.00211	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000506	0.00209	CcSEcCtD
Sulfamethoxazole—Pancytopenia—Doxorubicin—thyroid cancer	0.000503	0.00208	CcSEcCtD
Sulfamethoxazole—Renal failure—Epirubicin—thyroid cancer	0.000502	0.00207	CcSEcCtD
Sulfamethoxazole—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000501	0.00207	CcSEcCtD
Sulfamethoxazole—PTGS1—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.000498	0.011	CbGpPWpGaD
Sulfamethoxazole—Stomatitis—Epirubicin—thyroid cancer	0.000498	0.00206	CcSEcCtD
Sulfamethoxazole—Neutropenia—Doxorubicin—thyroid cancer	0.000496	0.00205	CcSEcCtD
Sulfamethoxazole—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000484	0.002	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000483	0.00199	CcSEcCtD
Sulfamethoxazole—Agranulocytosis—Epirubicin—thyroid cancer	0.000477	0.00197	CcSEcCtD
Sulfamethoxazole—Pneumonia—Doxorubicin—thyroid cancer	0.000475	0.00196	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Doxorubicin—thyroid cancer	0.000473	0.00195	CcSEcCtD
Sulfamethoxazole—Infestation—Doxorubicin—thyroid cancer	0.000473	0.00195	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000469	0.00193	CcSEcCtD
Sulfamethoxazole—Renal failure—Doxorubicin—thyroid cancer	0.000465	0.00192	CcSEcCtD
Sulfamethoxazole—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000463	0.00191	CcSEcCtD
Sulfamethoxazole—Stomatitis—Doxorubicin—thyroid cancer	0.000461	0.0019	CcSEcCtD
Sulfamethoxazole—Hepatitis—Epirubicin—thyroid cancer	0.000459	0.00189	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Epirubicin—thyroid cancer	0.000453	0.00187	CcSEcCtD
Sulfamethoxazole—Connective tissue disorder—Epirubicin—thyroid cancer	0.000451	0.00186	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Epirubicin—thyroid cancer	0.00045	0.00186	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000447	0.00185	CcSEcCtD
Sulfamethoxazole—NAT2—Metabolism—MINPP1—thyroid cancer	0.000446	0.00987	CbGpPWpGaD
Sulfamethoxazole—Agranulocytosis—Doxorubicin—thyroid cancer	0.000441	0.00182	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Epirubicin—thyroid cancer	0.000434	0.00179	CcSEcCtD
Sulfamethoxazole—UGT1A9—PPAR Alpha Pathway—CCND1—thyroid cancer	0.00043	0.00951	CbGpPWpGaD
Sulfamethoxazole—Eye disorder—Epirubicin—thyroid cancer	0.000429	0.00177	CcSEcCtD
Sulfamethoxazole—Tinnitus—Epirubicin—thyroid cancer	0.000428	0.00177	CcSEcCtD
Sulfamethoxazole—Hepatitis—Doxorubicin—thyroid cancer	0.000424	0.00175	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000419	0.00173	CcSEcCtD
Sulfamethoxazole—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000417	0.00172	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Doxorubicin—thyroid cancer	0.000416	0.00172	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Epirubicin—thyroid cancer	0.000414	0.00171	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Epirubicin—thyroid cancer	0.000413	0.00171	CcSEcCtD
Sulfamethoxazole—PTGS1—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.000413	0.00915	CbGpPWpGaD
Sulfamethoxazole—Chills—Epirubicin—thyroid cancer	0.000412	0.0017	CcSEcCtD
Sulfamethoxazole—Mental disorder—Epirubicin—thyroid cancer	0.000402	0.00166	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Doxorubicin—thyroid cancer	0.000401	0.00166	CcSEcCtD
Sulfamethoxazole—Malnutrition—Epirubicin—thyroid cancer	0.000399	0.00165	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—TPR—thyroid cancer	0.000397	0.0088	CbGpPWpGaD
Sulfamethoxazole—Eye disorder—Doxorubicin—thyroid cancer	0.000397	0.00164	CcSEcCtD
Sulfamethoxazole—Tinnitus—Doxorubicin—thyroid cancer	0.000396	0.00163	CcSEcCtD
Sulfamethoxazole—Tension—Epirubicin—thyroid cancer	0.000392	0.00162	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—PRKAR1A—thyroid cancer	0.000391	0.00866	CbGpPWpGaD
Sulfamethoxazole—Nervousness—Epirubicin—thyroid cancer	0.000388	0.0016	CcSEcCtD
Sulfamethoxazole—ALB—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000386	0.00856	CbGpPWpGaD
Sulfamethoxazole—Immune system disorder—Doxorubicin—thyroid cancer	0.000383	0.00158	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000382	0.00158	CcSEcCtD
Sulfamethoxazole—Chills—Doxorubicin—thyroid cancer	0.000381	0.00157	CcSEcCtD
Sulfamethoxazole—NAT2—Metabolism—NDUFA13—thyroid cancer	0.000379	0.00839	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metapathway biotransformation—CHST14—thyroid cancer	0.000377	0.00834	CbGpPWpGaD
Sulfamethoxazole—Mental disorder—Doxorubicin—thyroid cancer	0.000372	0.00154	CcSEcCtD
Sulfamethoxazole—Malnutrition—Doxorubicin—thyroid cancer	0.000369	0.00153	CcSEcCtD
Sulfamethoxazole—Tension—Doxorubicin—thyroid cancer	0.000362	0.0015	CcSEcCtD
Sulfamethoxazole—Nervousness—Doxorubicin—thyroid cancer	0.000359	0.00148	CcSEcCtD
Sulfamethoxazole—Vertigo—Epirubicin—thyroid cancer	0.000359	0.00148	CcSEcCtD
Sulfamethoxazole—Leukopenia—Epirubicin—thyroid cancer	0.000357	0.00148	CcSEcCtD
Sulfamethoxazole—NAT2—Metabolism—CHST14—thyroid cancer	0.000356	0.00789	CbGpPWpGaD
Sulfamethoxazole—Cough—Epirubicin—thyroid cancer	0.000348	0.00144	CcSEcCtD
Sulfamethoxazole—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000348	0.0077	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000348	0.00769	CbGpPWpGaD
Sulfamethoxazole—Convulsion—Epirubicin—thyroid cancer	0.000346	0.00143	CcSEcCtD
Sulfamethoxazole—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.000346	0.00766	CbGpPWpGaD
Sulfamethoxazole—Myalgia—Epirubicin—thyroid cancer	0.00034	0.0014	CcSEcCtD
Sulfamethoxazole—Arthralgia—Epirubicin—thyroid cancer	0.00034	0.0014	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000338	0.00139	CcSEcCtD
Sulfamethoxazole—Vertigo—Doxorubicin—thyroid cancer	0.000332	0.00137	CcSEcCtD
Sulfamethoxazole—Leukopenia—Doxorubicin—thyroid cancer	0.000331	0.00137	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Epirubicin—thyroid cancer	0.000326	0.00135	CcSEcCtD
Sulfamethoxazole—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000324	0.00718	CbGpPWpGaD
Sulfamethoxazole—Cough—Doxorubicin—thyroid cancer	0.000322	0.00133	CcSEcCtD
Sulfamethoxazole—Convulsion—Doxorubicin—thyroid cancer	0.00032	0.00132	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Epirubicin—thyroid cancer	0.00032	0.00132	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Epirubicin—thyroid cancer	0.000319	0.00132	CcSEcCtD
Sulfamethoxazole—Skin disorder—Epirubicin—thyroid cancer	0.000316	0.00131	CcSEcCtD
Sulfamethoxazole—Myalgia—Doxorubicin—thyroid cancer	0.000314	0.0013	CcSEcCtD
Sulfamethoxazole—Arthralgia—Doxorubicin—thyroid cancer	0.000314	0.0013	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000312	0.00129	CcSEcCtD
Sulfamethoxazole—Anorexia—Epirubicin—thyroid cancer	0.000311	0.00128	CcSEcCtD
Sulfamethoxazole—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000307	0.00679	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—PPARA activates gene expression—RXRA—thyroid cancer	0.000302	0.00669	CbGpPWpGaD
Sulfamethoxazole—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000301	0.00124	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—SLC5A5—thyroid cancer	0.000297	0.00659	CbGpPWpGaD
Sulfamethoxazole—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000297	0.00123	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Doxorubicin—thyroid cancer	0.000296	0.00122	CcSEcCtD
Sulfamethoxazole—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000296	0.00654	CbGpPWpGaD
Sulfamethoxazole—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000295	0.00122	CcSEcCtD
Sulfamethoxazole—Insomnia—Epirubicin—thyroid cancer	0.000295	0.00122	CcSEcCtD
Sulfamethoxazole—Skin disorder—Doxorubicin—thyroid cancer	0.000293	0.00121	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Epirubicin—thyroid cancer	0.00029	0.0012	CcSEcCtD
Sulfamethoxazole—Anorexia—Doxorubicin—thyroid cancer	0.000287	0.00119	CcSEcCtD
Sulfamethoxazole—NAT2—Metabolism—HPGD—thyroid cancer	0.000287	0.00636	CbGpPWpGaD
Sulfamethoxazole—Dyspepsia—Epirubicin—thyroid cancer	0.000287	0.00118	CcSEcCtD
Sulfamethoxazole—UGT1A9—NRF2 pathway—SLC5A5—thyroid cancer	0.000287	0.00635	CbGpPWpGaD
Sulfamethoxazole—Decreased appetite—Epirubicin—thyroid cancer	0.000283	0.00117	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000281	0.00116	CcSEcCtD
Sulfamethoxazole—Fatigue—Epirubicin—thyroid cancer	0.000281	0.00116	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000275	0.00113	CcSEcCtD
Sulfamethoxazole—Insomnia—Doxorubicin—thyroid cancer	0.000273	0.00113	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Doxorubicin—thyroid cancer	0.000269	0.00111	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000266	0.0011	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Doxorubicin—thyroid cancer	0.000265	0.0011	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Doxorubicin—thyroid cancer	0.000262	0.00108	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00026	0.00107	CcSEcCtD
Sulfamethoxazole—Fatigue—Doxorubicin—thyroid cancer	0.00026	0.00107	CcSEcCtD
Sulfamethoxazole—Urticaria—Epirubicin—thyroid cancer	0.000259	0.00107	CcSEcCtD
Sulfamethoxazole—CYP2C8—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000258	0.00572	CbGpPWpGaD
Sulfamethoxazole—Abdominal pain—Epirubicin—thyroid cancer	0.000258	0.00106	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Epirubicin—thyroid cancer	0.000258	0.00106	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—RXRA—thyroid cancer	0.00025	0.00553	CbGpPWpGaD
Sulfamethoxazole—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000247	0.00102	CcSEcCtD
Sulfamethoxazole—UGT1A9—NRF2 pathway—RXRA—thyroid cancer	0.000241	0.00533	CbGpPWpGaD
Sulfamethoxazole—Hypersensitivity—Epirubicin—thyroid cancer	0.00024	0.000991	CcSEcCtD
Sulfamethoxazole—Urticaria—Doxorubicin—thyroid cancer	0.00024	0.000989	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Doxorubicin—thyroid cancer	0.000238	0.000984	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Doxorubicin—thyroid cancer	0.000238	0.000984	CcSEcCtD
Sulfamethoxazole—Asthenia—Epirubicin—thyroid cancer	0.000234	0.000965	CcSEcCtD
Sulfamethoxazole—Pruritus—Epirubicin—thyroid cancer	0.000231	0.000952	CcSEcCtD
Sulfamethoxazole—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00023	0.00509	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000229	0.00507	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000224	0.00497	CbGpPWpGaD
Sulfamethoxazole—Diarrhoea—Epirubicin—thyroid cancer	0.000223	0.00092	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Doxorubicin—thyroid cancer	0.000222	0.000917	CcSEcCtD
Sulfamethoxazole—Asthenia—Doxorubicin—thyroid cancer	0.000216	0.000893	CcSEcCtD
Sulfamethoxazole—Dizziness—Epirubicin—thyroid cancer	0.000215	0.00089	CcSEcCtD
Sulfamethoxazole—Pruritus—Doxorubicin—thyroid cancer	0.000213	0.000881	CcSEcCtD
Sulfamethoxazole—UGT1A9—Biological oxidations—RXRA—thyroid cancer	0.000211	0.00468	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00021	0.00465	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000209	0.00464	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000209	0.00463	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—NRF2 pathway—NRG1—thyroid cancer	0.000208	0.00461	CbGpPWpGaD
Sulfamethoxazole—Vomiting—Epirubicin—thyroid cancer	0.000207	0.000855	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Doxorubicin—thyroid cancer	0.000206	0.000852	CcSEcCtD
Sulfamethoxazole—Rash—Epirubicin—thyroid cancer	0.000205	0.000848	CcSEcCtD
Sulfamethoxazole—Dermatitis—Epirubicin—thyroid cancer	0.000205	0.000847	CcSEcCtD
Sulfamethoxazole—Headache—Epirubicin—thyroid cancer	0.000204	0.000843	CcSEcCtD
Sulfamethoxazole—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000204	0.00451	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000202	0.00448	CbGpPWpGaD
Sulfamethoxazole—Dizziness—Doxorubicin—thyroid cancer	0.000199	0.000823	CcSEcCtD
Sulfamethoxazole—Nausea—Epirubicin—thyroid cancer	0.000194	0.000799	CcSEcCtD
Sulfamethoxazole—Vomiting—Doxorubicin—thyroid cancer	0.000192	0.000791	CcSEcCtD
Sulfamethoxazole—UGT1A9—PPARA activates gene expression—PPARG—thyroid cancer	0.000191	0.00422	CbGpPWpGaD
Sulfamethoxazole—Rash—Doxorubicin—thyroid cancer	0.00019	0.000785	CcSEcCtD
Sulfamethoxazole—Dermatitis—Doxorubicin—thyroid cancer	0.00019	0.000784	CcSEcCtD
Sulfamethoxazole—Headache—Doxorubicin—thyroid cancer	0.000189	0.00078	CcSEcCtD
Sulfamethoxazole—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000187	0.00413	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000183	0.00405	CbGpPWpGaD
Sulfamethoxazole—Nausea—Doxorubicin—thyroid cancer	0.000179	0.000739	CcSEcCtD
Sulfamethoxazole—PTGS1—Biological oxidations—RXRA—thyroid cancer	0.000172	0.00381	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00017	0.00377	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—TPR—thyroid cancer	0.000165	0.00365	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—PRKAR1A—thyroid cancer	0.000162	0.00359	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—PPARG—thyroid cancer	0.000158	0.00349	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—MINPP1—thyroid cancer	0.000155	0.00344	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000148	0.00329	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000146	0.00324	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000139	0.00307	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000138	0.00305	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—NDUFA13—thyroid cancer	0.000132	0.00292	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000129	0.00285	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—MINPP1—thyroid cancer	0.000126	0.0028	CbGpPWpGaD
Sulfamethoxazole—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000126	0.0028	CbGpPWpGaD
Sulfamethoxazole—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000126	0.0028	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—PTGS2—thyroid cancer	0.000124	0.00275	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—CHST14—thyroid cancer	0.000124	0.00275	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—SLC5A5—thyroid cancer	0.000124	0.00274	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000121	0.00267	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000118	0.00262	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000118	0.0026	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000112	0.00249	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Biological oxidations—RXRA—thyroid cancer	0.000111	0.00246	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—PTEN—thyroid cancer	0.000108	0.0024	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—NDUFA13—thyroid cancer	0.000108	0.00238	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—RXRA—thyroid cancer	0.000104	0.0023	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—CHST14—thyroid cancer	0.000101	0.00224	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—HPGD—thyroid cancer	0.0001	0.00221	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	9.62e-05	0.00213	CbGpPWpGaD
Sulfamethoxazole—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	9.46e-05	0.00209	CbGpPWpGaD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	9.39e-05	0.00208	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Biological oxidations—RXRA—thyroid cancer	9.05e-05	0.002	CbGpPWpGaD
Sulfamethoxazole—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	8.21e-05	0.00182	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—MINPP1—thyroid cancer	8.17e-05	0.00181	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—HPGD—thyroid cancer	8.15e-05	0.0018	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—MINPP1—thyroid cancer	8.12e-05	0.0018	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.11e-05	0.0018	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—PRKAR1A—thyroid cancer	7.29e-05	0.00162	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—TP53—thyroid cancer	7.03e-05	0.00156	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—NDUFA13—thyroid cancer	6.95e-05	0.00154	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—NDUFA13—thyroid cancer	6.91e-05	0.00153	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—MINPP1—thyroid cancer	6.65e-05	0.00147	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.61e-05	0.00146	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—PPARG—thyroid cancer	6.55e-05	0.00145	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CHST14—thyroid cancer	6.53e-05	0.00145	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CHST14—thyroid cancer	6.49e-05	0.00144	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	6.42e-05	0.00142	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	6.42e-05	0.00142	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	6.31e-05	0.0014	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—AKT1—thyroid cancer	6.24e-05	0.00138	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Biological oxidations—RXRA—thyroid cancer	5.97e-05	0.00132	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—TPR—thyroid cancer	5.74e-05	0.00127	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—NDUFA13—thyroid cancer	5.65e-05	0.00125	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PRKAR1A—thyroid cancer	5.65e-05	0.00125	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CHST14—thyroid cancer	5.32e-05	0.00118	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—HPGD—thyroid cancer	5.26e-05	0.00117	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—HPGD—thyroid cancer	5.23e-05	0.00116	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—PTGS2—thyroid cancer	5.15e-05	0.00114	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.12e-05	0.00113	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—IFNA2—thyroid cancer	4.83e-05	0.00107	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.81e-05	0.00106	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—TPR—thyroid cancer	4.68e-05	0.00104	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PRKAR1A—thyroid cancer	4.61e-05	0.00102	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—PTEN—thyroid cancer	4.5e-05	0.000995	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—MINPP1—thyroid cancer	4.38e-05	0.000971	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—SLC5A5—thyroid cancer	4.3e-05	0.000952	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—HPGD—thyroid cancer	4.28e-05	0.000949	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.27e-05	0.000946	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.25e-05	0.00094	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.17e-05	0.000924	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.04e-05	0.000894	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.03e-05	0.000892	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.73e-05	0.000826	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—RXRA—thyroid cancer	3.61e-05	0.0008	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.51e-05	0.000778	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—CHST14—thyroid cancer	3.51e-05	0.000776	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—SLC5A5—thyroid cancer	3.5e-05	0.000776	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.48e-05	0.00077	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.28e-05	0.000727	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—TPR—thyroid cancer	3.02e-05	0.00067	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—TPR—thyroid cancer	3.01e-05	0.000666	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	2.97e-05	0.000659	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PRKAR1A—thyroid cancer	2.96e-05	0.000655	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—RXRA—thyroid cancer	2.94e-05	0.000652	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.86e-05	0.000634	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—HPGD—thyroid cancer	2.83e-05	0.000626	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.7e-05	0.000597	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.68e-05	0.000594	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—AKT1—thyroid cancer	2.59e-05	0.000574	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—TPR—thyroid cancer	2.46e-05	0.000545	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.42e-05	0.000536	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PPARG—thyroid cancer	2.28e-05	0.000505	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—SLC5A5—thyroid cancer	2.26e-05	0.000501	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	2.26e-05	0.0005	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—SLC5A5—thyroid cancer	2.25e-05	0.000498	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.19e-05	0.000486	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.12e-05	0.00047	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.11e-05	0.000467	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—RXRA—thyroid cancer	1.9e-05	0.000421	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—RXRA—thyroid cancer	1.89e-05	0.000419	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PPARG—thyroid cancer	1.86e-05	0.000412	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.85e-05	0.00041	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.84e-05	0.000408	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.84e-05	0.000407	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—NRAS—thyroid cancer	1.8e-05	0.000399	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PTGS2—thyroid cancer	1.79e-05	0.000397	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.73e-05	0.000382	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—TPR—thyroid cancer	1.62e-05	0.000359	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.6e-05	0.000354	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PTEN—thyroid cancer	1.56e-05	0.000346	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—KRAS—thyroid cancer	1.55e-05	0.000343	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—RXRA—thyroid cancer	1.55e-05	0.000343	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.51e-05	0.000333	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PTGS2—thyroid cancer	1.46e-05	0.000324	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—TP53—thyroid cancer	1.38e-05	0.000305	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—HRAS—thyroid cancer	1.32e-05	0.000292	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PTEN—thyroid cancer	1.28e-05	0.000282	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.21e-05	0.000269	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PPARG—thyroid cancer	1.2e-05	0.000266	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PPARG—thyroid cancer	1.19e-05	0.000264	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—AKT1—thyroid cancer	1.16e-05	0.000258	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—RXRA—thyroid cancer	1.02e-05	0.000226	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PPARG—thyroid cancer	9.77e-06	0.000216	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PTGS2—thyroid cancer	9.45e-06	0.000209	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PTGS2—thyroid cancer	9.39e-06	0.000208	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—AKT1—thyroid cancer	9.02e-06	0.0002	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PTEN—thyroid cancer	8.24e-06	0.000182	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PTEN—thyroid cancer	8.19e-06	0.000181	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PTGS2—thyroid cancer	7.69e-06	0.00017	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—AKT1—thyroid cancer	7.35e-06	0.000163	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PTEN—thyroid cancer	6.7e-06	0.000148	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PPARG—thyroid cancer	6.44e-06	0.000143	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PTGS2—thyroid cancer	5.07e-06	0.000112	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—AKT1—thyroid cancer	4.75e-06	0.000105	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—AKT1—thyroid cancer	4.72e-06	0.000105	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PTEN—thyroid cancer	4.42e-06	9.79e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—AKT1—thyroid cancer	3.86e-06	8.56e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—AKT1—thyroid cancer	2.55e-06	5.64e-05	CbGpPWpGaD
